Connect with us

Press Releases

Zeiss and Boehringer Ingelheim Join Forces to Develop Early Detection of Eye Diseases and Prevent Vision Loss

ZEISS and Boehringer Ingelheim collaborate to detect and treat eye diseases early, preventing vision loss.




(PRESS RELEASE) ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic  collaboration to develop predictive analytics to enable early detection of eye diseases and more  personalized treatments to prevent vision loss for people with serious eye diseases. The partnership  brings together their leading expertise in ophthalmological technology, data analytics, algorithms and the development of first-in-class treatments to detect early and treat retinal diseases before irreversible  vision loss occurs. 

More than 300 million people worldwide are at risk today of losing their eyesight due to diseases  leading to functional loss of the retina. The number of people suffering from vision loss is rising due to  aging populations and widening health inequity gaps. Undiagnosed and untreated retinal diseases have a profound impact on people’s lives, potentially leading to isolation, loss of independence, depression and reduced quality of life. Unfortunately, diagnosis often occurs too late to prevent vision loss, and for  many conditions, no treatment is available at all. 

The new partnership will focus on identifying markers of early stages of retinal diseases by leveraging  ZEISS Medical Technology’s cloud-connected devices and AI-assisted analysis of massive image data  sets. This will provide a basis for clinical studies for development of more personalized and precise  treatments of early stages of chronic retinal disease as well as earlier detection and prediction  capabilities to preserve vision through new treatment pathways. 

“At ZEISS, we have long understood that where collaboration thrives, innovation emerges,“ said Euan S.  Thomson, Ph.D., Head of the Ophthalmology Strategic Business Unit and Head of the Digital Business  Unit for ZEISS Medical Technology. “With our announcement today with Boehringer Ingelheim, we’re  building on our strategy to innovate through partnerships in order to make breakthrough discoveries to  combat vision loss and improve people’s lives. Enabled by our ZEISS Medical Ecosystem and the  platform’s ability to aggregate massive data sets for analysis, we‘re strongly positioned to establish new  partnerships in pursuit of research yet to be investigated, to accelerate access to future technologies  and markets, and to help clinicians provide earlier detection and more personalized and precise care for  their patients.“ 

“Our partnership with ZEISS Medical Technology will allow us to develop precision therapies delivering  the right treatment for the right patient at the right time to prevent vision loss by intervening before  irreversible damage occurs. It is part of our commitment to champion early detection and treatment  and will contribute to transforming the lives of people with serious eye disease,” said Ulrike Graefe Mody, Ph.D., Head of Retinal Health at Boehringer Ingelheim. 

As a leading pioneer of science in optics for more than 100 years, ZEISS’s medical expertise and digital  leadership is foundational to the ZEISS Medical Ecosystem and its digitally connected workflows, which  are generating millions of data points every day. This connected and secure architecture integrates  diagnostic and therapeutic devices supported by a cloud-based platform in which data aggregation,  automation and AI analytics can be harnessed to help drive new discoveries to address the clinical  challenges facing healthcare professionals and ophthalmologists today. The ZEISS Medical Ecosystem is 


powered by the ZEISS Health Data Platform, designed to facilitate massive data aggregation at scale,  enabling new forms of partnerships focused on leveraging that data to generate new, transformative  insights. 

Boehringer Ingelheim has a leading understanding of disease biology aiming at a paradigm change in  retinal health through earlier detection and intervention to achieve meaningful improvements in  patient outcomes. Over the past decade, Boehringer Ingelheim has built a diverse pipeline, which focuses on three priority areas to address retinal conditions – the preservation of vascular function,  targeting inflammation and neuroprotection.



The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines






Get the most important news and business ideas for eyecare professionals every weekday from INVISION.


Most Popular